These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 6086215

  • 21. In vitro comparison of the activity of cefotaxime and desacetylated cefotaxime and of their combination.
    Nanetti A, La Placa M.
    J Chemother; 1990 Jun; 2(3):159-63. PubMed ID: 2380765
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against Bacteroides fragilis group organisms.
    Aldridge KE, Weeks LS, Stratton CW, Sanders CV.
    Diagn Microbiol Infect Dis; 1989 Jun; 12(2):165-70. PubMed ID: 2752714
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides.
    Seibert G, Limbert M, Winkler I, Dick T.
    Infection; 1983 Jun; 11(5):275-9. PubMed ID: 6315595
    [Abstract] [Full Text] [Related]

  • 27. In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin.
    Jones RN, Barry AL, Thornsberry C, Wilson HW.
    Antimicrob Agents Chemother; 1981 Dec; 20(6):760-8. PubMed ID: 6275785
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Synergistic activity of cefotaxime and desacetylcefotaxime against the Bacteroides fragilis group.
    Cornick NA, Gorbach SL.
    Diagn Microbiol Infect Dis; 1988 Jun; 10(2):81-4. PubMed ID: 3224498
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains].
    Mascellino MT, Prignano G, Iegri F, Lorenzi A.
    Boll Ist Sieroter Milan; 1982 Jun; 61(4):309-19. PubMed ID: 6100234
    [Abstract] [Full Text] [Related]

  • 32. In vitro activity and beta-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin.
    Scully BE, Jules K, Neu HC.
    Antimicrob Agents Chemother; 1983 Jun; 23(6):907-13. PubMed ID: 6311090
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Bacteriological and clinical studies on cefotaxime in obstetrics and gynecology (author's transl)].
    Ninomiya K, Hasegawa Y, Hamatani K, Nishio T.
    Jpn J Antibiot; 1981 Apr; 34(4):507-14. PubMed ID: 6270399
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF, Wildfeuer A.
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [MICs and MBCs of cefotaxime, desacetylcefotaxime and ceftriaxone against four principal bacteria causing meningitis].
    Deguchi K, Fukuyama S, Nishimura Y, Nishike A, Fukumoto T, Oda S, Sato S, Matsumoto Y, Ikegami R, Yokota N.
    Jpn J Antibiot; 1984 Sep; 37(9):1701-13. PubMed ID: 6096585
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.